🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Steven Cohen’s KALV Holdings & Trades

First Buy
Q2 2019
Duration Held
7 Quarters
Largest Add
Q4 2025
+2.28 M Shares
Current Position
2.14 M Shares
$43.02 M Value

Steven Cohen's KALV Position Overview

Steven Cohen (via Point72 Asset Management, L.P.) currently holds 2.14 M shares of KalVista Pharmaceuticals, Inc. (KALV) worth $43.02 M, representing 0.06% of the portfolio. First purchased in 2019-Q2, this short-term holding has been held for 7 quarters.

Based on 13F filings, Steven Cohen has maintained this position in KALV for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 2.28 M shares. Largest reduction occurred in Q1 2026, reducing 146,826 shares.

Analysis based on 13F filings available since 2013 Q2

Steven Cohen's KalVista Pharmaceuticals (KALV) Holding Value Over Time

Track share changes against reported price movement

Quarterly KalVista Pharmaceuticals (KALV) Trades by Steven Cohen

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q1 2026 -146,826 Reduce 6.43% 2.14 M $20.13
Q4 2025 +2.28 M New Buy 2.28 M $16.15
Q4 2022 -57,800 Sold Out 0 $0.00
Q3 2022 +57,800 New Buy 57,800 $14.52
Q4 2019 -87,000 Sold Out 0 $0.00
Q3 2019 -75,900 Reduce 46.59% 87,000 $11.60
Q2 2019 +162,900 New Buy 162,900 $22.15

Steven Cohen's KalVista Pharmaceuticals Investment FAQs

Steven Cohen first purchased KalVista Pharmaceuticals, Inc. (KALV) in Q2 2019, acquiring 162,900 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Steven Cohen has held KalVista Pharmaceuticals, Inc. (KALV) for 7 quarters since Q2 2019.

Steven Cohen's largest addition to KalVista Pharmaceuticals, Inc. (KALV) was in Q4 2025, adding 2,283,766 shares worth $36.88 M.

According to the latest 13F filing for Q1 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 2,136,940 shares of KalVista Pharmaceuticals, Inc. (KALV), valued at approximately $43.02 M.

As of the Q1 2026 filing, KalVista Pharmaceuticals, Inc. (KALV) represents approximately 0.06% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.

Steven Cohen's peak holding in KalVista Pharmaceuticals, Inc. (KALV) was 2,283,766 shares, as reported at the end of Q4 2025.